According to FutureWise analysis the market for artesunate tablet is expected to register a CAGR of 6.22% from 2023-2031.
The first-line treatment of severe malaria in children or adults, Artesunate is usually given in combination with another antimalarial drug. Where long-term care is not appropriate, artesunate may be administered as a single intramuscular injection or by rectal route (children under 6 years) prior to transferring care to a higher level facility. The treatment of severe malaria with artesunate is preferable to parenteral quinine. According to two large multicenter randomized controlled trials conducted in Africa and Asia. The benefits of artesunate were supported by the study results of Trial 2, which randomly assigned pediatric participants younger than 15 years of age with severe malaria to either artesunate or quinine treatment artesunate significantly reduced the death rate from severe malaria compared to quinine. In a systematic review of seven randomized controlled trials, this improvement in survival rates was consistent across all studies.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Artesunate Tablet Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Artesunate Tablet Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.